Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$515000.0.

  • Orchestra BioMed Holdings' Other Operating Expenses fell 15622.27% to -$515000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $137000.0, marking a year-over-year decrease of 9433.42%. This contributed to the annual value of $3.3 million for FY2024, which is 3734.28% up from last year.
  • Orchestra BioMed Holdings' Other Operating Expenses amounted to -$515000.0 in Q3 2025, which was down 15622.27% from -$36000.0 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Other Operating Expenses high stood at $1.2 million for Q3 2023, and its period low was -$601000.0 during Q1 2022.
  • Moreover, its 4-year median value for Other Operating Expenses was $166000.0 (2025), whereas its average is $288466.7.
  • Data for Orchestra BioMed Holdings' Other Operating Expenses shows a peak YoY increase of 66186.05% (in 2023) and a maximum YoY decrease of 53205.13% (in 2023) over the last 5 years.
  • Orchestra BioMed Holdings' Other Operating Expenses (Quarter) stood at $78000.0 in 2022, then crashed by 532.05% to -$337000.0 in 2023, then soared by 254.9% to $522000.0 in 2024, then plummeted by 198.66% to -$515000.0 in 2025.
  • Its Other Operating Expenses stands at -$515000.0 for Q3 2025, versus -$36000.0 for Q2 2025 and $166000.0 for Q1 2025.